Publisher
Springer International Publishing
Reference32 articles.
1. Chapman, R. H., Kumar, V. M., Whittington, M. D., & Pearson, S. D. (2021). Does cost-effectiveness analysis overvalue potential cures? Exploring alternative methods for applying a “shared savings” approach to cost offsets. Value in Health, 24(6), 839–845.
2. Cring, M. R., & Sheffield, V. C. (2020). Gene therapy and gene correction: Targets, progress, and challenges for treating human diseases. Gene Therapy., 29, 3–12.
3. de la Fuente, J., Gluckman, E., Makani, J., Telfer, P., Faulkner, L., Corbacioglu, S., et al. (2020). The role of haematopoietic stem cell transplantation for sickle cell disease in the era of targeted disease-modifying therapies and gene editing. The Lancet Haematology, 7(12), e902–e911.
4. De La Morena, M. T., & Gatti, R. A. (2011). A history of bone marrow transplantation. Hematology/Oncology Clinics, 25(1), 1–15.
5. Delhove, J., Osenk, I., Prichard, I., & Donnelley, M. (2019). Public acceptability of gene therapy and gene editing for human use: A systematic review. Human Gene Therapy, 31(1–2), 20–46.